Seizure medications and psilocybin.
31 records in this group. 3 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Also searched as anticonvulsant · antiepileptic · seizure medication · anti-seizure · epilepsy medication
01 What the evidence covers
Best evidence available per medication| 1 | Open-label trial |
| 2 | Case reports Case reports or online surveys |
| 28 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZPartial-onset (focal) seizures
Not studied with psilocybin; it can cause sleepiness and mood changes, so added sedation is possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures associated with Lennox-Gastaut syndrome; Seizures associated with Dravet syndrome
It may slow how the body clears psilocybin, raising levels (not studied with psilocybin). Also, its label lists sleepiness, suicidal thoughts and liver enzyme rises.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial seizures with complex symptoms; Generalized tonic-clonic seizures
It may weaken psilocybin by speeding how the body clears psilocybin (untested). Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures in adults
Not studied with psilocybin; it causes sleepiness and dizziness. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures in Lennox-Gastaut syndrome (add-on)
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures, including Lennox-Gastaut syndrome, akinetic, myoclonic and absence seizures; Panic disorder
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Anxiety disorders; Alcohol withdrawal symptoms
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures (age 4 and older)
It may lower psilocybin levels by speeding how the body clears psilocybin (untested). Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Absence (petit mal) seizures
Not studied with psilocybin; no linking mechanism is described. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial seizures in adults (severe, refractory epilepsy); Seizures of Lennox-Gastaut syndrome in children (add-on treatment)
Not studied with psilocybin; its label warns of rare aplastic anemia and liver failure. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures associated with Dravet syndrome; Seizures associated with Lennox-Gastaut syndrome
Not studied with psilocybin; it acts on the same serotonin receptors as psilocybin, so added or competing effects are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Generalized tonic-clonic status epilepticus; Prevention and treatment of seizures during neurosurgery
It may lower psilocybin levels by speeding how the body clears psilocybin (untested). Also, rapid infusion can cause severe low blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Nerve pain after shingles (postherpetic neuralgia); Partial-onset seizures (add-on treatment)
It may add drowsiness and does not act on serotonin (not studied with psilocybin). Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures of CDKL5 deficiency disorder (age 2 and older)
Its effect on psilocybin is unknown; it causes sleepiness and sedation. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures; Primary generalized tonic-clonic seizures (add-on therapy)
Not studied with psilocybin; no linking mechanism is described. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures; Primary generalized tonic-clonic seizures
In 34 reports with classic psychedelics like psilocybin, none described a seizure; most noted no change. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset seizures; Myoclonic seizures in juvenile myoclonic epilepsy (add-on)
Not studied with psilocybin. Also, it can cause sleepiness, irritability and mood changes, and sometimes psychotic symptoms or suicidal thoughts.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Sedation, anxiety relief, and amnesia before or during surgery and medical procedures; Starting general anesthesia
In a small study, midazolam with psilocybin left the experience conscious but partly impaired memory of it; it also adds sedation.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures
Not studied with psilocybin; it can lower blood sodium, so heavy water drinking during a session could lower it further.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset seizures (ages 4 and older); Primary generalized tonic-clonic seizures (add-on, ages 12 and older)
Not studied with psilocybin, and any effect on how the body clears psilocybin is untested. Also, its boxed warning covers serious psychiatric reactions, including aggression.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- PhenobarbitalEvidence: No psilocybin data
Seizures in newborns (neonatal seizures; injectable form)
Not studied with psilocybin; it speeds the breakdown of drugs, so lower psilocybin levels are possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures (tonic-clonic and complex partial/focal); Seizures during or after brain surgery (neurosurgery)
Not studied with psilocybin; it strongly speeds drug breakdown, so lower psilocybin levels are possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Diabetic nerve pain (diabetic peripheral neuropathy); Nerve pain after shingles (postherpetic neuralgia)
Its sleepiness may add to psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Epilepsy (grand mal, psychomotor and focal seizures)
Not studied with psilocybin; it speeds drug breakdown, so weaker or shorter psilocybin effects are possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures of Lennox-Gastaut syndrome (add-on treatment, age 1 and older)
Not studied with psilocybin; it weakly speeds drug breakdown, so slightly lower psilocybin levels are possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Seizures of Dravet syndrome (taken with clobazam, age 6 months and older)
Not studied with psilocybin; it blocks an enzyme that clears psilocybin, so higher levels are possible. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial (focal) seizures, as add-on therapy (age 12+)
Not studied with psilocybin; it may add to sedation. Also, it can provoke seizures, even in people without epilepsy.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset seizures; Generalized tonic-clonic seizures
No direct interaction with psilocybin is expected. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Complex partial (focal) seizures; Absence seizures (simple and complex), alone or with other seizure types
In one case, psilocybin mushrooms with valproate, phenelzine and other drugs had no noticeable effect. It may also slow how the body clears psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Refractory complex partial (focal) seizures (add-on, age 2 and older); Infantile spasms (age 1 month to 2 years)
Not studied with psilocybin, and any effect on it is unknown. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial (focal) seizures in adults, as add-on therapy
No known direct interaction with psilocybin; it can reduce sweating and cause overheating. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 31 | Withdrawal or rebound if stopped abruptly |
| 29 | Sedating or CNS depressant |
| 26 | Psychiatric reactions |
| 12 | Speeds up drug metabolism |
| 8 | Liver injury |
| 3 | Dehydration or electrolyte risk |
| 3 | Lowers seizure threshold or carries seizure risk |
| 2 | Lowers blood pressure or causes orthostasis |
| 2 | UGT inhibition (theoretical effect on psilocin levels) |
| 1 | Anticholinergic |
| 1 | QT-prolonging |
| 1 | Raises blood pressure or heart rate |
| 1 | Serotonergic |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 15 of the 31 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Benzodiazepines4 shared
- Mood stabilizers3 shared
Records reviewed 2026-10-03 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z